logo
Plus   Neg
Share
Email

Novavax Reports Positive Phase 1 Data For NVX-CoV2373 - Quick Facts

Novavax, Inc. (NVAX) said, NVX-CoV2373, the company's recombinant COVID-19 vaccine candidate adjuvanted with Matrix-M, was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera in phase 1 portion of the Phase 1/2 clinical trial. The study was conducted in 131 healthy adults ages 18-59 years. All subjects developed anti-spike IgG antibodies after a single dose of vaccine, many of them also developing wild-type virus neutralizing antibody responses, and after dose 2, 100% of participants developed wild-type virus neutralizing antibody responses.

"The Phase 1 data demonstrate that NVX-CoV2373 with our Matrix-M adjuvant is a well-tolerated COVID-19 vaccine with a robust immunogenicity profile," said Gregory Glenn, President, Research and Development at Novavax.

The trial was supported by funding from the Coalition for Epidemic Preparedness Innovations and was conducted at two sites in Australia.

Shares of Novavax were up more than 10% after hours.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Volkswagen Group were gaining around 3 percent in German trading after the automotive giant Thursday reported market recovery in the third quarter with improved deliveries in the month of September. For the first nine months of fiscal 2020, the company, meanwhile reported sharply lower earnings with weak revenues and sales volume. Comcast Corp. on Thursday reported a 37 percent decline in profit for the third quarter from last year, hurt primarily by revenue decline at NBCUniversal. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also declared a quarterly dividend. In the pre-market trade, CMCSA is trading at $42.83, up $0.85 or 2.02 percent. Regeneron announced positive results from its late stage COVID-19 outpatient trial, indicating that its antibody cocktail therapy significantly reduced virus levels and need for further medical attention. The trial results showed that investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints.
Follow RTT